SMOLDERING PLASMA CELL MYELOMA
Clinical trials for SMOLDERING PLASMA CELL MYELOMA explained in plain language.
Never miss a new study
Get alerted when new SMOLDERING PLASMA CELL MYELOMA trials appear
Sign up with your email to follow new studies for SMOLDERING PLASMA CELL MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stop precancerous blood disorder from turning deadly
Disease control OngoingThis study is testing whether two drugs, isatuximab and lenalidomide, can delay or prevent high-risk smoldering multiple myeloma from progressing to active, symptomatic cancer. It involves 61 adults whose condition shows signs it is likely to worsen soon. Participants receive the…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Early trial tests common arthritis Drug's potential to hold off blood cancer
Disease control OngoingThis small, early-stage study is testing whether leflunomide, an anti-inflammatory drug used for rheumatoid arthritis, can delay the progression of high-risk smoldering multiple myeloma to active, symptomatic cancer. Researchers are giving the drug daily to a small group of eligi…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Drug trial aims to delay blood cancer progression
Disease control OngoingThis study is testing whether the drug leflunomide can delay or prevent smoldering multiple myeloma from progressing to active cancer. It involves 27 African-American and European-American adults with high-risk smoldering myeloma who take a daily pill. The main goal is to see if …
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Early trial aims to stop Slow-Growing blood cancer in its tracks
Disease control OngoingThis small, early-stage study is testing whether the immunotherapy drug pembrolizumab can help control smoldering multiple myeloma, a slow-growing blood condition with a high risk of turning into active cancer. The trial will give the drug to 20 adults with intermediate or high-r…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC